<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003252</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066134</org_study_id>
    <secondary_id>RNSMC-AM9702</secondary_id>
    <secondary_id>ALZA-RNSMC-AM9702</secondary_id>
    <secondary_id>NCI-V98-1390</secondary_id>
    <nct_id>NCT00003252</nct_id>
  </id_info>
  <brief_title>Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy</brief_title>
  <official_title>A Phase IV Open Label Study of the Effects of a Five Minute Infusion Time for Ethyol (Amifostine) in Patients Undergoing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells&#xD;
      from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase IV trial to study the effectiveness of amifostine in treating patients with&#xD;
      cancer who have neurological changes caused by chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility and tolerability of administering amifostine by&#xD;
      intravenous infusion over 5 minutes in cancer patients undergoing chemotherapy.&#xD;
&#xD;
      OUTLINE: This is an open label, controlled study. Patients receive intravenous amifostine&#xD;
      over 5 minutes 30 minutes prior to chemotherapy. Patients are followed for one month post&#xD;
      treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically proven cancer No brain or other&#xD;
        CNS metastases (including prior treated metastases)&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy: Not&#xD;
        specified Hematopoietic: Not specified Hepatic: No grade 3 or greater hepatic dysfunction&#xD;
        Renal: No hypercalcemia Cardiovascular: No uncontrolled hypotension Other: Not pregnant or&#xD;
        nursing Effective contraceptive method must be used by fertile patients No psychosis No&#xD;
        severe concurrent illness other than neoplasia No epileptic seizures during the previous&#xD;
        year, migraines, gastrointestinal obstructions, or other causes of vomiting No prior or&#xD;
        concurrent amifostine contraindications No prior known contraindications or sensitivity to&#xD;
        dexamethasone, granisetron, ondansetron, prochlorperazine, diphenhydramine, cimetidine, or&#xD;
        magnesium&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified&#xD;
        Endocrine therapy: No prior estrogen within 24 hours of amifostine therapy Radiotherapy:&#xD;
        Not specified Surgery: Not specified Other: No prior alcohol, disulphiram, tetracycline, or&#xD;
        erythromycin within 24 hours of amifostine therapy No prior antiemetics such as&#xD;
        benzodiazepines, antipsychotics, anticonvulsants, or antihistamines within 24 hours of&#xD;
        amifostine therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward H. Kaplan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rush North Shore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush North Shore Medical Center</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2004</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

